Deletsit 1000

General characteristics. Structure:

Each ampoule (4 ml) contains:
Active agent: sincaline альфосцерат – 1000 mg;
Excipients: water for injections – to 4 ml.

Description:
Transparent colourless solution.

Pharmacological properties:

Pharmacodynamics. Sincaline альфосцерат (L - -glitserilfosforilkholin) is pro-medicine from which by hydrolysis sincaline — the predecessor of acetylcholine is released. The last is an agonist of all subtypes of holinoretseptor.
Sincaline альфосцерат contains 40,5% of the sincaline on weight which is released from connection in a brain; sincaline participates in biosynthesis of acetylcholine, is a donator of methyl groups, participates in other plastic reactions in an organism. Alfostserat-ion it is metabolized to glycerophosphate ion.
Acetylcholine directly participates in transfer of nervous impulse both in central, and in a peripheral nervous system. Glycerophosphate joins in various metabolic ways, including participates in phosphatidylsincaline synthesis (one of phospholipids of cellular membranes). Thus, drug affects cholinergic transfer of nervous impulse, plasticity of a membrane of neuron.
It is supposed that drug reduces cognitive disturbances at degenerative and vascular damages of a brain (including at cerebrovascular insufficiency and some forms of dementia).

Pharmacokinetics. Absorption at intake about 95%. Gets through a blood-brain barrier (concentration in a brain — 45% of that in plasma). Both sincaline, and glycerophosphate ion join in the general metabolism therefore it is not possible to monitor their real elimination from an organism. However it is known that they are metabolized to carbon of dioxide, water, phosphates and nitrogen-containing products.

Indications to use:

As a part of complex therapy:
•   A psychoorganic syndrome against the background of degenerative diseases and involutional processes of a brain or cerebrovascular insufficiency, including primary and secondary senile cognitive disturbances.
•   Multiinfarctive dementia.

Route of administration and doses:

The drug is administered intramusculary or intravenously (kapelno).
Solution to infusions and intramuscular introduction is applied at acute states or impossibility to accept drug inside.
Enter intramusculary or intravenously (kapelno) in a dose of 1000 mg (1 ampoule) in days. At intravenous administration contents of one ampoule (4 ml) dissolve 0,9% of solution of sodium of chloride in 50 ml; infusion speed — 60-80 drops a minute. Treatment duration usually makes 10 days, then pass to administration of drug inside. The general course of treatment drug makes 3–6 months.

Side effects:

From the alimentary system: gastritis, peptic ulcer of a stomach, lock, diarrhea, dryness of a mucous membrane of an oral cavity, pharyngitis.
From a nervous system: headache, drowsiness, sleeplessness, aggression, nervousness, ischemia of a brain, spasm, hyperkinesia, dizziness.
From integuments: rash.
Others: increase of an urination, allergic reactions.

Interaction with other medicines:

Medicinal interaction is not established.
Influence on ability to manage vehicles or to be engaged in other types of activity
 It is necessary to be careful at control of vehicles or occupations other types of activity demanding the increased concentration of attention and/or speed of psychomotor reactions.

Contraindications:

Hypersensitivity to drug components, a hemorrhagic stroke (an acute stage), pregnancy, breastfeeding, children's age.
Use during pregnancy and a lactation
Use of drug during pregnancy and breastfeeding is contraindicated.

Overdose:

Data on overdose are absent.
At overdose are shown: a gastric lavage, reception of the adsorbing medicines (for example, absorbent carbon), symptomatic therapy. Efficiency of dialysis is not established.

Storage conditions:

At a temperature not over 25 ºС. To store in the place, unavailable to children! Period of validity 3 years. Not to use after a period of validity.

Issue conditions:

According to the recipe

Packaging:

Solution for infusions and intramuscular introduction of 1000 mg / 4 ml. On 4 ml of solution in ampoules neutral colourlessly flew down type I.
On 3 or 5 ampoules in a blister strip packaging together with the application instruction in a pack cardboard.